Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
RELATED ARTICLES
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
